{Reference Type}: Case Reports
{Title}: Vismodegib as an adjuvant treatment for periorbital basal cell carcinoma: a case report and review of literature.
{Author}: Jabbehdari S;Veluvolu M;Kornhauser T;Jennings TA;Pemberton JD;
{Journal}: Ann Transl Med
{Volume}: 12
{Issue}: 3
{Year}: 2024 Jun 10
{Factor}: 3.616
{DOI}: 10.21037/atm-23-1589
{Abstract}: <B>UNASSIGNED: </B>Basal cell carcinoma (BCC) is the most common cancer type worldwide. Although there are several treatment options for the treatment of BCC, selecting the best treatment option for periorbital BCC is challenging and it varies case by case. More than half of periocular BCC cases initially occur on the inner angle and lower lid. The treatment options for BCC include radical surgical excision using Mohs micrographic technique, radiotherapy, neoadjuvant vismodegib, imiquimod, and combination therapy followed by reconstruction for functionality and aesthetic outcome. Selection of each treatment varies based on the severity and extension of BCC.<BR><B>UNASSIGNED: </B>We report a case of periorbital BCC invading the left lower eyelid in a 50-year-old Caucasian male which was initially excised a few years ago, and, following recurrence, the patient underwent Mohs micrographic surgery. Due to a recurrence after Mohs micrographic surgery, treatment with oral vismodegib was started, which led to near-total tumor shrinkage. To determine the outcome of periorbital BCC treated with vismodegib, we reviewed the literature on the periorbital BCC treated with vismodegib, their follow-up period, outcome, and whether they were metastatic or had recurrence.<BR><B>UNASSIGNED: </B>Neoadjuvant vismodegib, followed by surgery excision, such as Mohs micrographic surgery, has shown a promising clinical and aesthetic outcome in the treatment of periorbital BCC.